Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Orangetheory Brand President Lauren Cody on the fitness industry's shift from chasing aesthetics to prioritizing longevity and measurable health and wellness.
Peachtree Group CEO Greg Friedman breaks down the Fed's rate decision and the Senate's housing affordability bill and what it means for commercial real estate.
Nodi is giving kids a safe way to stay connected before they're ready for a smartphone. CEO Pascal Leonard Blum breaks down how the device works for families.
From coast to coast, gas prices are telling different stories. AAA's Aixa Diaz explains what's behind the numbers and what it means for American drivers.
AutoStore’s CPO Parth Joshi explains its new AI software layer designed to optimize warehouse robots in real time and unlock smarter, more efficient fulfillment
ROC CEO B. Scott Swann joins us live from the NYSE to discuss the company's IPO and how VisionAI is transforming facial recognition for defense and security.
